Issuance of new european patent bolsters ip protection for jaguar health in the treatment of congenital diarrheal disorders (cdds)

New patent issued for core rare disease target indication for crofelemer jaguar has approximately 200 patents issued and pending jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome (sbs) and microvillus inclusion disease (mvid), an ultrarare cdd, in the us, eu, and middle east/north africa regions, with proof-of-concept results expected before the end of 2024 and throughout 2025 san francisco, ca / accesswire / july 31, 2024 / napo pharmaceuticals (napo), a jaguar health (nasdaq:jagx) (jaguar) family company, today announced that the european patent office has issued a new patent to napo for methods of preventing, ameliorating and/or treating diarrhea associated with congenital diarrheal disorders (cdds) using a proanthocyanidin polymer composition such as crofelemer, napo's novel plant-based prescription drug. "we are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of mvid, an ultrarare cdd," said lisa conte, jaguar's founder, president, and ceo.
JAGX Ratings Summary
JAGX Quant Ranking